BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.